贝那普利辅助治疗扩张型心肌病心力衰竭的效果及对患者hs-CRP、BNP水平的影响

Effect of benazepril as adjuvant therapy for heart failure in dilated cardiomyopathy and its effect on hs-CRP and BNP levels in patients

目的探讨贝那普利辅助治疗扩张型心肌病(DCM)心力衰竭的效果及对患者高敏C反应蛋白(hs-CRP)、B型钠尿肽(BNP)水平的影响。方法选取2016年1月至2018年1月于本院诊治的扩张型心肌病并心功能衰竭的患者60例,按照随机数字表法分为对照组(左卡尼汀治疗,n=30)和观察组(贝那普利联合左卡尼汀治疗,n=30)。比较两组患者疗效、6 min步行距离(6MWT)、明尼苏达心力衰竭生活质量表评分(MLHFQ)、肺功能(FEV1、FEV1/FVC、FEV1%)、hs-CRP及BNP水平。结果观察组患者治疗总有效率高于对照组(P<0.05);观察组患者6MWT长于对照组,MLHFQ评分低于对照组(P<0.05);观察组患者FEV1、FEV1/FVC、FEV1%水平高于对照组,hs-CRP、BNP水平均低于对照组(P<0.05)。结论贝那普利联合左卡尼汀治疗能提高DCM并心力衰竭患者疗效,且可改善生活质量及心肺功能。

Objective To investigate the effect of benazepril in the adjuvant treatment of heart failure in dilated cardiomyopathy(DCM)and its effect on the levels of high-sensitivity C-reactive protein(hs-CRP)and B-type natriuretic peptide(BNP)in patients.Methods 60 patients with dilated cardiomyopathy and heart failure who were treated in our hospital from January 2016 to January 2018 were selected and randomly divided into control group(levocarnitine treated,n=30)and observation group(benazepril combined with levocarnitine treated,n=30).Efficacy,6-min walking distance(6MWT),Minnesota Heart Failure Quality of Life Questionnaire(MLHFQ)score,lung function(FEV1,FEV1/FVC,FEV1%),hs-CRP and BNP levels were compared between the two groups.Results The total effective rate of the patients in the observation group was higher than that in the control group(P<0.05).The 6MWT of the patients in the observation group was longer than that in the control group,and the MLHFQ score was lower than that in the control group(P<0.05).The levels of FEV1,FEV1/FVC,FEV1%in the observation group were higher than those in the control group,while the levels of hs-CRP and BNP were lower than those in the control group(P<0.05).Conclusion Benazepril combined with Levocarnitine can improve the efficacy,quality of life and cardiopulmonary function of patients with DCM and heart failure.